GLEN ALLEN, Va.--(BUSINESS WIRE)--Feb 8, 2010 - Osteologix, Inc. (OTCBB:OLGX) today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview and update at the 12th Annual BIO CEO & Investor Conference being held this week at the Waldorf Astoria Hotel in New York City. [more]
NEW HAVEN, Conn., Feb 8, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will present a corporate and clinical update at the 12th Annual BIO CEO and Investor Conference at The Waldorf Astoria hotel in New York City on Tuesday, February 9, 2010 at 3:30 p.m. Eastern Standard Time. [more]
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb 8, 2010 - Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) biotechnology company, will present at the 12th Annual BIO CEO & Investor Conference tomorrow, Tuesday, February 9, 2010 at 3:00 PM EST. [more]
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 8, 2010 - Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's product development programs at 10:30 a.m. EST on Tuesday, February 9, 2010, at the 12th Annual BIO CEO & Investor Conference in New York City. [more]
AMSTERDAM--(BUSINESS WIRE)--Feb 8, 2010 - AMT is a leader in the field of gene therapy. Its first product is in registration in EU for Lipoprotein Lipase Deficiency, an orphan condition. AMT's other development programmes include: Hemophilia, Parkinson's Disease, Duchenne and Porphyria. AMT's gene therapy approach offers a safe, long-term (potentially lifetime) therapy from a single treatment. This could fundamentally alter treatment approaches in target indications. [more]
USINESS WIRE)--Feb 8, 2010 - UBS The UBS Global Healthcare Services Conference will feature presentations and updates from senior management from more than 120 of the leading healthcare services firms around the world, companies that continue to shape this dynamic field. Participants from acute care, alternate site, distribution, healthcare REITs, information technology, laboratory services, long-term care, managed care, pharmaceutical services, staffing and other healthcare service sectors will attend, including: [more]
NEW YORK--(BUSINESS WIRE)--Feb 8, 2010 - The 20th Annual UBS Global Healthcare Services Conference opens today at the Grand Hyatt in New York City and runs through Wednesday, February 10th. The conference will feature presentations and updates from senior management from more than 120 of the leading healthcare services firms around the world, companies that continue to shape this dynamic field. Presenting companies include: [more]
PRINCETON, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:CVD) today announced that it will present at the 20th Annual Global Healthcare Services Conference on Tuesday, February 9, 2010 at 12:30 p.m. ET. Investors may access a live webcast of the presentation at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early. [more]
OMAHA, Neb., Feb. 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that Craig Tuttle, President and Chief Executive Officer, will be presenting a corporate overview of the company at the 12th Annual BIO CEO & Investor Conference. Transgenomic's presentation will take place at 11:30 a.m. EST on Tuesday, February 9, 2010 at The Waldorf-Astoria in New York City, NY. [more]
TORONTO, Feb. 5, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) today announced that Dr. Tony Cruz, Chairman and Chief Executive Officer, will participate on a panel entitled "Alzheimer's Disease: A Panel to Remember," at the upcoming 12th Annual BIO CEO & Investor Conference on Tuesday, February 9th, 2010 at 9:00am (Eastern time) at the Waldorf Astoria in New York. [more]
ALLSCHWIL/BASEL, SWITZERLAND - 05 February 2010 - Actelion Ltd (SIX: ATLN) announced today that Roland Haefeli, Vice Pesident, Investor Relations & Public Affairs and member of the Actelion executive committee, will present at the upcoming BIO CEO & Investor Conference on Monday, February 8, 2010 at 9:30 a.m. Eastern time / 3:30 p.m. local time at the Waldorf Astoria Hotel in New York City. [more]
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb 5, 2010 - Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 12th Annual BIO CEO & Investor Conference will be webcast and may be accessed at www.hgsi.com [more]
SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (NASDAQ:RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the 12th Annual BIO CEO and Investor Conference. [more]
SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on innovative oncology therapies, today announced that Ronald Martell, chief executive officer, will provide a corporate overview at the 12th Annual BIO CEO and Investor Conference on Tuesday, February 9, 2010 at 1:00 p.m. Eastern Time at the Waldorf-Astoria in New York City. [more]
ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12th Annual BIO CEO & Investor Conference on February 8th, 2010 at 10:00 am local time. [more]
LONDON and PALO ALTO, Calif., Feb. 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth, Ph.D., chief executive officer, will deliver a corporate overview and business update at the 12th Annual BIO CEO & Investor Conference. The conference will be held February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City. [more]
SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST. [more]
IRVINE, Calif.--(BUSINESS WIRE)--Feb 5, 2010 - Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a focus in oncology, announced today that Rajesh C. Shrotriya MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, will provide an overview of the Company's business strategy at the 2010 BIO CEO Investor Conference on Tuesday, February 9, 2010, at 11:30am Eastern Time. [more]
ALISO VIEJO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (NASDAQ:CLRT) , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Chief Executive Officer Ron Andrews is scheduled to make an investor presentation at the UBS 20th Annual Global Healthcare Services Conference at 10:00 am EST on Wednesday, February 10. The conference will be held February 8-10 at the Grand Hyatt Hotel in New York City. [more]
WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will make a corporate presentation at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf-Astoria in New York. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
